-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Lynwood Capital Management Inc. Takes $315,000 Position in Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD)
Lynwood Capital Management Inc. Takes $315,000 Position in Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD)
Lynwood Capital Management Inc. bought a new stake in shares of Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD – Get Rating) during the 1st quarter, HoldingsChannel.com reports. The firm bought 31,454 shares of the company's stock, valued at approximately $315,000.
Several other institutional investors have also made changes to their positions in IQMD. Dupont Capital Management Corp acquired a new stake in shares of Intelligent Medicine Acquisition during the 4th quarter valued at about $255,000. Wolverine Asset Management LLC acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $99,000. Radcliffe Capital Management L.P. acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $2,970,000. Starboard Value LP acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $952,000. Finally, Saba Capital Management L.P. acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $15,539,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.
Get Intelligent Medicine Acquisition alerts:Intelligent Medicine Acquisition Stock Performance
NASDAQ:IQMD opened at $10.05 on Friday. Intelligent Medicine Acquisition Corp. has a 12 month low of $9.86 and a 12 month high of $10.93. The company's 50-day moving average price is $10.00 and its two-hundred day moving average price is $9.97.
Intelligent Medicine Acquisition Profile
(Get Rating)Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science.
Further Reading
- Get a free copy of the StockNews.com research report on Intelligent Medicine Acquisition (IQMD)
- Procter's Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Want to see what other hedge funds are holding IQMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD – Get Rating).
Receive News & Ratings for Intelligent Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Lynwood Capital Management Inc. bought a new stake in shares of Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD – Get Rating) during the 1st quarter, HoldingsChannel.com reports. The firm bought 31,454 shares of the company's stock, valued at approximately $315,000.
據HoldingsChannel.com報道,林伍德資本管理公司在第一季度購買了智能醫藥收購公司(納斯達克代碼:IQMD-GET Rating)的新股。該公司購買了31,454股該公司股票,價值約315,000美元。
Several other institutional investors have also made changes to their positions in IQMD. Dupont Capital Management Corp acquired a new stake in shares of Intelligent Medicine Acquisition during the 4th quarter valued at about $255,000. Wolverine Asset Management LLC acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $99,000. Radcliffe Capital Management L.P. acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $2,970,000. Starboard Value LP acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $952,000. Finally, Saba Capital Management L.P. acquired a new position in Intelligent Medicine Acquisition in the fourth quarter valued at about $15,539,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.
其他幾家機構投資者也改變了他們在IQMD的頭寸。杜邦資本管理公司(DuPont Capital Management Corp)在第四季度收購了智能醫療收購公司的新股份,價值約255,000美元。金剛狼資產管理有限責任公司在第四季度收購了智能醫療公司,價值約99,000美元。Radcliffe Capital Management L.P.在第四季度收購了智能醫療領域的一個新頭寸,價值約297萬美元。Starboard Value LP在第四季度收購了智能醫療領域的一個新頭寸,價值約952,000美元。最後,Saba Capital Management L.P.在第四季度收購了智能醫療領域的一個新頭寸,價值約15,539,000美元。25.60%的股票目前由機構投資者和對衝基金持有。
Intelligent Medicine Acquisition Stock Performance
智能醫藥收購股票表現
NASDAQ:IQMD opened at $10.05 on Friday. Intelligent Medicine Acquisition Corp. has a 12 month low of $9.86 and a 12 month high of $10.93. The company's 50-day moving average price is $10.00 and its two-hundred day moving average price is $9.97.
納斯達克:IQMD上週五開盤報10.05美元。智能醫藥收購公司的股價為9.86美元的12個月低點和10.93美元的12個月高位。該公司的50日移動均線價格為10.00美元,200日移動均線價格為9.97美元。
Intelligent Medicine Acquisition Profile
智能醫療採集配置文件
Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science.
智能醫藥收購公司沒有重大業務。公司專注於與一家或多家企業進行合併、資本換股、資產收購、股票購買、重組或相關業務合併。它打算確定生命科學領域的商業機會。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Intelligent Medicine Acquisition (IQMD)
- Procter's Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
- 免費獲取StockNews.com關於智能醫學獲取(IQMD)的研究報告
- 寶潔第四季度收益開始疲軟
- MarketBeat:回顧一週7/25-7/29
- 在投資INTC股票之前,你必須問一個問題
- 家得寶:引領熊市的美麗而乏味的股票
- CRISPR治療公司可能是隱藏在平坦視線中的登月計劃嗎?
Want to see what other hedge funds are holding IQMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD – Get Rating).
想看看還有哪些對衝基金持有IQMD嗎?訪問HoldingsChannel.com獲取智能醫藥收購公司(納斯達克代碼:iqmd-Get Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Intelligent Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
接受《智能醫藥採購日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對智能醫藥收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧